Kymera Therapeutics Quarterly Cash Flow Statement
NASDAQ: KYMRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kymera Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Kymera Therapeutics generated -$54.1 million of operating cash flow and spent $473,000 on capital expenditures. That left free cash flow of -$54.5 million, a free-cash-flow margin of -83.9% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Kymera Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -61.21M | -69.23M | -86.98M | -82.17M | -76.61M | -65.58M | -70.75M | -62.49M | -42.06M | -48.56M | -14.37M | -52.87M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 2.03M | 2.02M | 2.03M | 2.15M | 2.08M | 2.05M | 1.99M | 1.99M | 1.94M | 1.46M | 891.00K | 895.00K |
| Stock-Based Compensation | 18.94M | 16.01M | 14.45M | 15.80M | 15.42M | 14.23M | 13.80M | 14.90M | 14.34M | 11.97M | 10.90M | 11.65M |
| Change in Working Capital | 9.77M | -36.31M | 8.98M | -2.10M | 24.06M | -7.10M | -1.08M | -3.26M | -15.18M | -26.58M | 21.62M | 2.33M |
| Operating Cash Flow | -54.06M | -88.84M | -66.75M | -27.11M | -59.88M | -79.15M | -61.78M | -50.19M | -42.94M | -39.59M | 8.04M | -31.65M |
| Capital Expenditures | -473.00K | -434.00K | -106.00K | -181.00K | -695.00K | -467.00K | -936.00K | 189.00K | -4.69M | -7.40M | -11.63M | -8.08M |
| Investing Cash Flow | 20.05M | -142.84M | -394.40M | -235.30M | 60.02M | 48.62M | 68.57M | -157.68M | 15.64M | -330.61M | 18.95M | 60.51M |
| Financing Cash Flow | 14.42M | 18.77M | 705.22M | 39.51M | 245.73M | 258.00K | 2.77M | 250.92M | 1.41M | 353.76M | 1.93M | -206.00K |
| Net Change in Cash | -19.60M | -212.91M | 244.07M | -222.90M | 245.86M | -30.28M | 9.55M | 43.05M | -25.88M | -16.44M | 28.93M | 28.66M |
| Free Cash Flow | -54.54M | -89.27M | -66.85M | -27.29M | -60.58M | -79.62M | -62.72M | -50.00M | -47.63M | -46.99M | -3.58M | -39.73M |
This table shows 12 quarterly periods of Kymera Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow KYMR's reporting calendar. What is a cash flow statement?